
    
      This is a randomized, double-blind, parallel group, placebo-controlled study designed to
      evaluate efficacy and safety of tralokinumab administered subcutaneously in subjects with
      uncontrolled asthma on inhaled corticosteroid plus long-acting Î²2-agonist and having a
      history of asthma exacerbations. Approximately 770 subjects will be randomized globally.
      Subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at
      the study site, over a 52-week treatment period.
    
  